Replimune Group, Inc. (REPL) |
| 4.53 -0.1 (-2.16%) 10-10 16:00 |
| Open: | 4.66 |
| High: | 4.73 |
| Low: | 4.495 |
| Volume: | 1,781,814 |
| Market Cap: | 354(M) |
| PE Ratio: | -1.4 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 6.33 |
| Resistance 1: | 5.10 |
| Pivot price: | 4.34 |
| Support 1: | 3.12 |
| Support 2: | 2.60 |
| 52w High: | 17 |
| 52w Low: | 2.68 |
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Financials
| EPS | -3.240 |
| Book Value | 4.330 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -36.5 |
| Return on Equity (ttm) | -73.4 |
Company news
Wed, 08 Oct 2025
REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Fri, 03 Oct 2025
Replimune Group, Inc. (NASDAQ:REPL) Receives Average Rating of "Hold" from Analysts - MarketBeat
Mon, 22 Sep 2025
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Sun, 21 Sep 2025
Replimune (REPL): Assessing Valuation After FDA Setback and Legal Challenges to RP1 Approval - simplywall.st
Sat, 20 Sep 2025
Replimune: Further Uncertainty Of RP1 Warrants Move To 'Hold' Rating (NASDAQ:REPL) - Seeking Alpha
Sat, 20 Sep 2025
Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman - PR Newswire
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
